Minerva Pediatrics最新文献

Complicated pneumonia requiring invasive procedures in children in the post-COVID period: monocentric experience.

IF 1

Minerva Pediatrics Pub Date : 2025-03-25 DOI: 10.23736/S2724-5276.25.07722-5

Chiara Costantini, Riccardo Guanà, Elisa Zambaiti, Elena Stanton, Luca Lonati, Steffi Shilly, Fabrizio Gennari, Federico Scottoni

{"title":"Complicated pneumonia requiring invasive procedures in children in the post-COVID period: monocentric experience.","authors":"Chiara Costantini, Riccardo Guanà, Elisa Zambaiti, Elena Stanton, Luca Lonati, Steffi Shilly, Fabrizio Gennari, Federico Scottoni","doi":"10.23736/S2724-5276.25.07722-5","DOIUrl":"https://doi.org/10.23736/S2724-5276.25.07722-5","url":null,"abstract":"Background: The Severe Acute Respiratory Syndrome virus (SARS-CoV-2) had a great impact in the worldwide population. Because of personal protective equipment (PPE), children have not been exposed to the commonly circulating respiratory viruses, with an effect on pneumonia disease spreading. The aim of our study was to evaluate the different distribution of invasive procedures for complicated pneumonia in pre, intra and post pandemic period.Methods: We conducted a retrospective analysis in children who underwent invasive procedures for complicated pneumonia, focusing on the winter season. Three periods were identified: pre-SARS-CoV-2 (14 months), pandemic (11 months) and post-SARS-CoV-2 (5 months). The invasive procedures considered were thoracentesis, chest tube placement, and video-assisted thoracoscopic surgery (VATS).Results: A total of 67 children were admitted to our Institution for complicated pneumonia between November 2017 and March 2023 with a mean of 2.6, 1 and 4.4 per months respectively, in pre-pandemic and post-SARS-CoV-2. A chest tube was placed in 24% of pre-pandemic patients, 9% of pandemic and 50% of post-pandemic (P=0.002). Fifty percent of post-pandemic patients required VATS (P=0.014). Chest CT scans demonstrated necrotizing pneumonia with higher frequency in post-SARS-CoV-2 period (P=0.031).Conclusions: PPE preserved from SARS-CoV-2 but influenced the spread of other pathogens. We reported an increasing number of complicated pneumonias requiring surgery and of necrotizing pneumonia in the post-pandemic period.","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal dexmedetomidine for procedural sedation in infants: a retrospective study.

IF 1

Minerva Pediatrics Pub Date : 2025-03-25 DOI: 10.23736/S2724-5276.25.07768-7

Gianluca Dini, Federica Celi, Maria G Santini, Carla M Semeraro

{"title":"Intranasal dexmedetomidine for procedural sedation in infants: a retrospective study.","authors":"Gianluca Dini, Federica Celi, Maria G Santini, Carla M Semeraro","doi":"10.23736/S2724-5276.25.07768-7","DOIUrl":"https://doi.org/10.23736/S2724-5276.25.07768-7","url":null,"abstract":"Background: Infants undergoing magnetic resonance imaging (MRI) often require pharmacological sedation. Dexmedetomidine is an alpha-2 receptor agonist that is frequently used to sedate children and infants, because the neonatologist can easily adjust sedation depth, the patient maintains spontaneous breathing, and awakens rapidly afterwards. The present study evaluates whether dexmedetomidine could safely be used as the sole sedative for preterm and term-born infants less than 80 weeks' postmenstrual age undergoing diagnostic procedures.Methods: We performed a retrospective monocentric analysis of 50 preterm and term-born infants (<80 weeks' postmenstrual age) who were sedated with dexmedetomidine for a brain MRI from October 2019 to March 2024.Results: Successful imaging was achieved in all cases. The median dexmedetomidine loading dose was 2.75 μg/kg (2-4 μg/kg). Bradycardia was observed in four out of 50 patients (8%) and none of them required atropine.Conclusions: These results suggest that dexmedetomidine can be safely used for procedural sedation in the high-risk cohort of preterm and term-born infants less than 80 weeks' postmenstrual age.","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fetal alcohol spectrum disorders prevention: is it necessary?

IF 1

Minerva Pediatrics Pub Date : 2025-03-25 DOI: 10.23736/S2724-5276.25.07839-5

Patrizia Balbinot, Gianni Testino

引用次数: 0

Metabolomics and pediatric cardiology.

IF 1

Minerva Pediatrics Pub Date : 2025-03-25 DOI: 10.23736/S2724-5276.25.07751-1

Roberta Pintus, Angelica Dessì, Alice Bosco, Michele Mussap, Pier P Bassareo, Vassilios Fanos

引用次数: 0

Biomarkers to predict kidney outcomes in children with IgA vasculitis.

IF 1

Minerva Pediatrics Pub Date : 2025-03-25 DOI: 10.23736/S2724-5276.24.07715-2

Chloe E C Williams, Hannah Ging, Nikolaos Skoutelis, Julien Marro, Lydia Roberts, Andrew J Chetwynd, Louise Oni

{"title":"Biomarkers to predict kidney outcomes in children with IgA vasculitis.","authors":"Chloe E C Williams, Hannah Ging, Nikolaos Skoutelis, Julien Marro, Lydia Roberts, Andrew J Chetwynd, Louise Oni","doi":"10.23736/S2724-5276.24.07715-2","DOIUrl":"https://doi.org/10.23736/S2724-5276.24.07715-2","url":null,"abstract":"Immunoglobulin A (IgA) vasculitis (IgAV, also known as Henoch-Schoenlein purpura, HSP) is a small vessel vasculitis, most commonly presenting in childhood. In most, it has a straightforward, self-limiting disease course, however some children may develop kidney involvement (IgAV-N) which occurs 4-12 weeks following disease onset and remains the biggest contributor to long-term morbidity. Therefore, children undergo a six-month period of kidney monitoring to identify nephritis via surrogate markers including urinalysis and blood pressure measurements. On-going efforts aim at earlier identification and prevention of nephritis during the window of opportunity between disease onset and established nephritis. By identifying those at highest risk of developing poorer kidney outcomes, the number of children developing chronic kidney disease stage 5 (CKD5) as a result of IgAV-N may be reduced. This review summarizes the latest scientific evidence that support the use of novel biomarkers which may allow nephritis to be identified earlier compared to traditional markers, as well as the risk stratification of children with established IgAV-N. These biomarkers may also enhance the evolving understanding of underlying inflammatory pathways. Promising novel urinary markers of early nephritis include angiotensinogen, Gd-IgA1, various complement proteins, and MCP-1, and serum markers such as α-SMA, C-Met, PTX-3, MMP-9, MRP 8/14, and adiponectin may help identify those at risk of developing CKD5. Prospective, longitudinal, international validation studies are required to investigate these markers further, including exploration of implementation into clinical practice.","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143702309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multicomponent food supplement with quercetin Phytosome®, zinc and vitamin C may be favorable in managing children with seasonal allergic rhinitis: a pilot study.

IF 1

Minerva Pediatrics Pub Date : 2025-03-13 DOI: 10.23736/S2724-5276.25.07806-1

Maria A Tosca, Chiara Ferrecchi, Vincenzo Meleca, Matteo Naso, Giorgio Ciprandi

引用次数: 0

Point-of-care ultrasound recognition of massive thymic hyperplasia.

IF 1

Minerva Pediatrics Pub Date : 2025-03-13 DOI: 10.23736/S2724-5276.25.07821-8

Marco Denina, Giulia Tosoni, Irene Raffaldi, Angelo G Delmonaco, Antonio Pizzol, Matilde Piglione, Claudia Bondone

引用次数: 0

The role of combining anti-reflux and anti-drooling surgery in neurologically impaired children with chronic lung aspiration.

IF 1

Minerva Pediatrics Pub Date : 2025-02-18 DOI: 10.23736/S2724-5276.24.07669-9

Angelo Zarfati, Sonia Battaglia, Daniela Camanni, Ottavio Adorisio, Francesco DE Peppo

{"title":"The role of combining anti-reflux and anti-drooling surgery in neurologically impaired children with chronic lung aspiration.","authors":"Angelo Zarfati, Sonia Battaglia, Daniela Camanni, Ottavio Adorisio, Francesco DE Peppo","doi":"10.23736/S2724-5276.24.07669-9","DOIUrl":"https://doi.org/10.23736/S2724-5276.24.07669-9","url":null,"abstract":"Background: Hospitalizations for children with neurological impairments (NI) are frequently caused by chronic lung aspiration (CLA). Gastroesophageal reflux disease (GERD) and posterior drooling are two of the causes of CLA. Combination of anti-reflux procedure, i.e. Nissen fundoplication (NF), and anti-drooling surgery, i.e. subtotal functional sialoadenectomy (SFS), could effectively address both components of CLA. This study presents outcomes of the combined surgical treatment, especially focusing on long-term results. The aim of this article is to present our experience using a combination of NF and SFS as treatments for CLA caused by refractory GERD and drooling in pediatric patients with NI.Methods: Retrospective analysis of consecutive patients treated in our pediatric tertiary center (period: 2012-20). Inclusion criteria: NI patients with CLA, simultaneous refractory GERD and drooling, minimal follow-up ≥12 months.Results: Seventeen patients included (12 males): all patients had dysphagia and fifteen (88%) had vomiting/regurgitation. Four patients (24%) had ≤1 aspiration pneumonia/year, while 13 (76%) had recurring episodes (≥2 per year). The median age at surgery was 8.2 years old (0.8-18.5). Three patients (18%) had early major complications (Clavien-Dindo ≥IIIa). After surgery, study population showed a significant decrease in vomiting/regurgitation (P=0.0004), posterior drooling (P=0.0039), and mean episodes of pneumonia/year (P=0.0009). One patient (6%) needed re-do fundoplication for GERD recurrence. One patient (6%) had tracheostomy. No surgery related mortality was recorded.Conclusions: The combination of NF and SFS offers a chance to face up to chronic pulmonary aspiration, proving to effectively treating both GER and posterior drooling, with an acceptably low complication rate.","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143443002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An intranasal multicomponent medical device (Saflovir®) may represent a valuable option in managing upper airways diseases. 鼻内多组分医疗器械（Saflovir®）可能是治疗上呼吸道疾病的一个重要选择。

IF 1

Minerva Pediatrics Pub Date : 2025-02-18 DOI: 10.23736/S2724-5276.25.07788-2

Giorgio Ciprandi, Lorenzo Drago, Ignazio LA Mantia, Maria A Tosca

引用次数: 0

Management of nocturnal enuresis in children.

IF 1

Minerva Pediatrics Pub Date : 2025-02-18 DOI: 10.23736/S2724-5276.25.07812-7

Ignazio Cammisa, Margherita Zona, Pietro Ferrara

{"title":"Management of nocturnal enuresis in children.","authors":"Ignazio Cammisa, Margherita Zona, Pietro Ferrara","doi":"10.23736/S2724-5276.25.07812-7","DOIUrl":"https://doi.org/10.23736/S2724-5276.25.07812-7","url":null,"abstract":"Introduction: Nocturnal enuresis is defined as involuntary urination during sleep in children, particularly those aged 5 years or older. Treatment approaches include both pharmacological and non-pharmacological methods, with choices depending on the type and severity of nocturnal enuresis, as well as family dynamics. This review evaluates current knowledge on nocturnal enuresis treatment in children.Evidence acquisition: A systematic review of studies published from 2000 to 2024 was conducted, assessing both pharmacological and non-pharmacological interventions.Evidence synthesis: Nocturnal enuresis in children has been treated with various pharmacological and non-pharmacological interventions. Non-pharmacological therapies for nocturnal enuresis offer effective, low-risk options for managing this common pediatric condition, particularly when used in combination. Enuresis alarm therapy, considered the first-line treatment, has demonstrated success rates between 50% and 70%. On the other hand, bladder training, pelvic floor retraining and dietary modification play a supportive role in nocturnal enuresis management. Pharmacological interventions mainly include desmopressin and anticholinergics. Combination therapies, particularly desmopressin and anticholinergics, have demonstrated superior efficacy and faster results compared to monotherapy.Conclusions: A variety of pharmacological and non-pharmacological treatments have been developed to manage nocturnal enuresis and improve the quality of life for affected children. The primary goal for healthcare providers is to tailor a treatment plan to each child, taking into consideration the individual needs of the child and their family.","PeriodicalId":56337,"journal":{"name":"Minerva Pediatrics","volume":" ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143443001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0